

Research article

Open Access

## Bone turnover markers are correlated with total skeletal uptake of $^{99m}\text{Tc}$ -methylene diphosphonate ( $^{99m}\text{Tc}$ -MDP)

Janaka Lenora\*<sup>1</sup>, Kristina Norrgren<sup>2</sup>, Ola Thorsson<sup>2</sup>, Per Wollmer<sup>2</sup>, Karl J Obrant<sup>1</sup> and Kaisa K Ivaska<sup>1</sup>

Address: <sup>1</sup>Department of Orthopaedics, Malmö University Hospital, Lund University, SE 20502 Malmö, Sweden and <sup>2</sup>Department of Clinical Physiology, Malmö University Hospital, Lund University, SE 20502 Malmö, Sweden

Email: Janaka Lenora\* - [Robolge.Lenora@med.lu.se](mailto:Robolge.Lenora@med.lu.se); Kristina Norrgren - [Kristina.Norrgren@telia.com](mailto:Kristina.Norrgren@telia.com); Ola Thorsson - [Ola.Thorsson@med.lu.se](mailto:Ola.Thorsson@med.lu.se); Per Wollmer - [Per.Wollmer@med.lu.se](mailto:Per.Wollmer@med.lu.se); Karl J Obrant - [Karl.Obrant@med.lu.se](mailto:Karl.Obrant@med.lu.se); Kaisa K Ivaska - [kakaiv@utu.fi](mailto:kakaiv@utu.fi)

\* Corresponding author

Published: 30 March 2009

Received: 21 November 2008

*BMC Medical Physics* 2009, **9**:3 doi:10.1186/1756-6649-9-3

Accepted: 30 March 2009

This article is available from: <http://www.biomedcentral.com/1756-6649/9/3>

© 2009 Lenora et al; licensee BioMed Central Ltd.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/2.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

### Abstract

**Background:** Skeletal uptake of  $^{99m}\text{Tc}$  labelled methylene diphosphonate ( $^{99m}\text{Tc}$ -MDP) is used for producing images of pathological bone uptake due to its incorporation to the sites of active bone turnover. This study was done to validate bone turnover markers using total skeletal uptake (TSU) of  $^{99m}\text{Tc}$ -MDP.

**Methods:** 22 postmenopausal women (52–80 years) volunteered to participate. Scintigraphy was performed by injecting 520 MBq of  $^{99m}\text{Tc}$ -MDP and taking whole body images after 3 minutes, and 5 hours. TSU was calculated from these two images by taking into account the urinary loss and soft tissue uptake. Bone turnover markers used were bone specific alkaline phosphatase (S-Bone ALP), three different assays for serum osteocalcin (OC), tartrate resistant acid phosphatase 5b (S-TRACP5b), serum C-terminal cross-linked telopeptides of type I collagen (S-CTX-I) and three assays for urinary osteocalcin (U-OC).

**Results:** The median TSU of  $^{99m}\text{Tc}$ -MDP was 23% of the administered activity. All bone turnover markers were significantly correlated with TSU with r-values from 0.52 ( $p = 0.013$ ) to 0.90 ( $p < 0.001$ ). The two resorption markers had numerically higher correlations (S-TRACP5b  $r = 0.90$ , S-CTX-I  $r = 0.80$ ) than the formation markers (S-Total OC  $r = 0.72$ , S-Bone ALP  $r = 0.66$ ), but the difference was not statistically significant. TSU did not correlate with age, weight, body mass index or bone mineral density.

**Conclusion:** In conclusion, bone turnover markers are strongly correlated with total skeletal uptake of  $^{99m}\text{Tc}$ -MDP. There were no significant differences in correlations for bone formation and resorption markers. This should be due to the coupling between formation and resorption.

### Background

Bone metabolism can be assessed by biochemical means using bone turnover markers (BTM) measured in serum or urine [1]. BTMs can be used in the monitoring of antire-

sorptive therapy [2,3] and there is increasing evidence that at least some BTMs can be predictive for bone loss [4] and fracture [5,6]. They are, however, also subjected to rapid changes due to reasons other than bone metabolism [7],

such as diurnal variation, other tissue damages and food intake [8]. Some of the BTMs reflect bone formation, while others are associated to bone resorption. However, both formation and resorption markers are usually affected by changes in turnover due to the coupling between these two processes [1].

Several attempts have been made to assess the skeletal metabolic activity by using skeletal uptake of radiolabelled, bone seeking, substances. Bisphosphonates, structurally similar to the inorganic pyrophosphates in bone matrix, have high affinity to bind to bone mineral [9]. Especially, they bind to the exposed sites that undergo high bone turnover. Technetium-99m ( $^{99m}\text{Tc}$ ) labelled diphosphonates are commonly used in scintigraphic uptake studies to detect lesions in conditions such as cancer metastasis, occult fractures and osteomyelitis due to their high affinity to metabolically active sites in bone. In these procedures the skeletal or extra-osseous accumulation of  $^{99m}\text{Tc}$  labelled methylene diphosphonate ( $^{99m}\text{Tc}$ -MDP) is used to identify the lesions as "hot spots" [10,11]. In earlier studies the measurement of 24-hour whole body retention of  $^{99m}\text{Tc}$ -MDP was used to assess the skeletal metabolism [12,13], before introducing the regional quantification of  $^{99m}\text{Tc}$ -MDP activity by D'Addabbo et al [14] and Brenner et al [15]. These techniques have been found to be useful techniques for estimating skeletal turnover rate at the time of the measurement. The regional quantification after 5-hours has the advantage over 24-hour retention that it directly gives a measure of skeletal uptake and a shorter time period is needed. To the best of our knowledge, the correlation between bone metabolism assessed by skeletal uptake of  $^{99m}\text{Tc}$ -MDP and by bone turnover markers has been evaluated only in a few studies [13,16-18].

This study was designed to assess the correlation between the skeletal uptake of  $^{99m}\text{Tc}$ -MDP, and nine bone turnover markers including markers of bone formation and bone resorption and urinary osteocalcin. Our aim was to elucidate if markers reflect total skeletal turnover determined by skeletal uptake of  $^{99m}\text{Tc}$ -MDP. Furthermore, we aimed to investigate if uptake of  $^{99m}\text{Tc}$ -MDP is more related to bone formation or resorption, assuming that if any of the bone formation markers had a significantly greater correlation with TSU, over the others; it could have been regarded as a relatively specific measure of bone formation.

## Methods

### Participating women

22 postmenopausal women who had sought medical advice or treatment for minor orthopaedic complains (such as non-fracture trauma, back pain, vertebral fractures, ankle fractures) at least 6 months before the recruit-

ment and who had never been treated with bisphosphonates were selected from the registers of the orthopaedic clinic at Malmö University Hospital. Patients with primary hyperparathyroidism, hyperthyroidism, osteomalacia, chronic malnutrition, any malignancy, hepatic cirrhosis, joint prosthesis; or patients who had been treated with systemic estrogens, therapeutic calcium, vitamin D or corticosteroids within the last one year were not included. When the study was started, they were free from the condition that had originally brought them to the clinic. Fractures within 2 years prior to the study were also recorded.


### Bone mineral density

Areal bone mineral density (BMD) of total body, lumbar spine, femoral neck and bone mineral content (BMC) of the total body were measured by dual-energy x-ray absorptiometry (DXA) (Lunar DPX-L<sup>®</sup> Madison, USA). The precision of measurements assessed by duplicate measurements on 15 elderly women after repositioning were 0.5% for total body BMD, 1.3% for total body BMC, 1.2% for lumbar spine BMD, and 3.9% for femoral neck BMD.

### Bone scintigraphy

Bone scintigraphy procedure was performed within 28 days after the DXA scanning according to a method described by Brenner et al [15]. An injection of 520 ( $517 \pm 15$ ) MBq of  $^{99m}\text{Tc}$ -MDP (Medronate<sup>®</sup>, Amersham international) was given. The radio activity was measured in the syringe both before and after injection to enable an accurate determination of injected activity. Whole body imaging was performed directly (3 minutes) after injection and 5 hours after injection. A double-headed gamma camera system (Siemens Multispect 2) equipped with low energy high-resolution collimators was used for the scan. The scan speed was 40 cm/min for the image at 3 minutes and 15 cm/min for the image after 5 hours. The images were stored in a 1024 × 256 matrix for image processing.

Regions of interest (ROI) were drawn in the anterior and posterior images to quantify the activity in whole body, urinary bladder, and the adductor muscles of both thighs, (Figure 1) as described by Brenner *et al.* [15]. The geometric mean of the anterior and posterior image was used in the calculation of activity content and the 3-minute image was used as a reference to calculate the percentage uptake in the later image. For all data the numbers of counts in the regions were corrected for decay of  $^{99m}\text{Tc}$ . The soft tissue activity was calculated from the adductor compartment of both thighs as follows: activity of adductor muscles at 5 hours divided by the activity of adductor muscles at 3 minutes and multiplied by whole body activity at 3 minutes. All activity was considered to be excreted from the body, only via urine. The excretion was calcu-



**Figure 1**

**Whole body scan images of one of the study participants at 3 minutes (A) and at 5 hours (B).** Regions of interest (ROI) were drawn in the anterior and posterior images to quantify the activity in whole body, urinary bladder (X), and the adductor muscles of both thighs (Y), as described by Brenner *et al.*[15] Z = area marked for counting the background radiation.

lated from the difference in whole body activity between two imaging times. Correction for radioactive decay and scan speed was done. The total skeletal uptake (TSU) of  $^{99m}\text{Tc}$ -MDP was calculated as (whole body radioactivity at 3 min – urinary excretion – soft tissue uptake at 5 hour)/ whole body radioactivity at 3 min  $\times$  100% [15].

#### **Serum and urine samples for bone turnover markers**

Non-fasting blood samples were collected before the scintigraphy procedure (at 9.00 am). Serum was separated within 2 hours after phlebotomy. Non-fasting urine samples were collected at 9.00 am. Serum and urine samples were stored at  $-80^{\circ}\text{C}$  for the analysis of bone turnover markers.

#### **Bone turnover markers**

All the analyses were done at the same time. Bone-specific alkaline phosphatase (S-Bone ALP) was determined by using Metra BAP immunoassay (Quidel Corporation),

with an intra- and inter- assay CV of 3.6% and 4.4%, respectively. Serum intact osteocalcin [S-OC(1–49)], serum total osteocalcin (S-Total OC) and serum total gamma-carboxylated osteocalcin (S-cOC) were determined by previously described, in-house protocols with intra- and inter- assay CV of less than 5% and 8%, respectively, for all the assays [19].

Serum C-terminal cross-linking telopeptides of type I collagen (S-CTX-I) were determined by Elecsys  $\beta$ -Cross Laps<sup>®</sup> immunoassay (Roche diagnostics) with intra- and inter-assay CV of 5.9% and 5.8%, respectively. Serum tartrate-resistant acid phosphatase 5b (S-TRACP5b) was assessed by a solid phase, immunofixed, enzyme activity assay as described earlier [20] with an intra- and inter- assay CV of 1.8% and 2.2%, respectively.

Three different assays of urinary osteocalcin, total osteocalcin (U-TotalOC), long osteocalcin (U-LongOC) and

mid osteocalcin (U-MidOC) were analyzed as previously published with intra- and inter- assay CVs of 14% and < 27% (U-TotalOC), 4.3% and < 14% (U-LongOC), and 1.7% and < 12% (U-MidOC), respectively [21].

Urinary creatinine was measured by the kinetic Jaffe reaction with a Beckman synchron LX20-4, with CVs of 3% or less. All the measurements of urinary osteocalcin were corrected for urinary creatinine and expressed as ratios.

### Statistical analysis

Statistica for Windows (version 7.1, Stat Soft Inc) software was used for the statistical analysis. The results were expressed as median and inter quartile range (IQR). The correlations of bone turnover markers and the total skeletal uptake of  $^{99m}\text{Tc}$ -MDP were assessed by using Spearman rank correlations. Group comparisons were done using Mann-Whitney U test. P-values less than 0.05 were considered statistically significant.

### Ethics

All steps of the study were approved by the ethical review committee, Lund University, Sweden in accordance with the Declaration of Helsinki. Informed, consent was obtained from each of the participants prior to the study.

## Results

### Basic characteristics

The median age of the women was 65 years (range 52–80). The median total body BMD was 1.02 g/cm<sup>2</sup> (IQR 0.97 – 1.08) (Table 1). Eight women had osteoporosis, defined as T score  $\leq$  -2.5 at spine (n = 7) or at femoral neck (n = 1). Eight women had sustained a fracture within 2 years (range 0.5 – 2) before the study, including vertebral compression fractures (n = 6), distal radius fracture (n = 1) and ankle fracture (n = 1). Of them, five women had osteoporosis based on lumbar spine or femoral neck T-score.

### Scintigraphy

The median value for total skeletal uptake of  $^{99m}\text{Tc}$ -MDP at 5 hours was 23% (IQR (18.8 – 27.9)). There were no statistically significant associations between total skeletal uptake and total body BMD, total body BMC, body weight, BMI or age (Table 1).


### Bone turnover markers

All the bone turnover markers were highly correlated with total skeletal uptake of  $^{99m}\text{Tc}$ -MDP with r-values from 0.52 for U-TotalOC (p = 0.013) to 0.90 for S-TRACP5b (p < 0.001) (Table 1 and Figure 2). The two resorption markers had numerically higher correlations (S-TRACP5b r = 0.90, S-CTX-I r = 0.80) than the formation markers (S-

**Table 1: Baseline characteristics, scintigraphy results and bone turnover markers of participants (n = 22).**

	Median (inter quartile range)	Correlations with TSU of $^{99m}\text{Tc}$ -MDP	
		r	p
<b>Anthropometry</b>			
Age (years)	65 (59 – 73)	0.06	0.79
Height (cm)	162 (158 – 167)	0.03	0.90
Weight (kg)	65 (60 – 79)	-0.08	0.071
BMI (kg/m <sup>2</sup> )	25.4 (22.8 – 29.1)	-0.18	0.43
<b>Bone mass</b>			
Total body BMC (g)	2075 (1933 – 2208)	-0.23	0.30
Total body BMD (g/cm <sup>2</sup> )	1.02 (0.97 – 1.08)	-0.36	0.10
<b>Scintigraphy</b>			
Total skeletal uptake (%)	22.9 (18.8 – 27.9)	-	-
<b>Bone Formation markers</b>			
S-Bone ALP (U/L)	23.0 (17.0 – 28.0)	<b>0.66</b>	<b>&lt; 0.001</b>
S-Total OC ( $\mu\text{g/L}$ )	5.8 (5.0 – 8.5)	<b>0.72</b>	<b>&lt; 0.001</b>
S-OC(1–49) ( $\mu\text{g/L}$ )	3.0 (2.2 – 5.0)	<b>0.65</b>	<b>&lt; 0.01</b>
S-cOC ( $\mu\text{g/L}$ )	6.9 (5.4 – 9.1)	<b>0.67</b>	<b>&lt; 0.001</b>
<b>Bone resorption markers</b>			
S-TRACP5b (U/L)	3.1 (2.5 – 3.9)	<b>0.90</b>	<b>&lt; 0.001</b>
S-CTX-I (ng/L)	228 (173 – 326)	<b>0.80</b>	<b>&lt; 0.001</b>
<b>Urine osteocalcin</b>			
U-Total OC/crea ( $\mu\text{g/nmol}$ )	28.3 (19.7 – 32.0)	<b>0.52</b>	<b>0.013</b>
U-Mid OC/crea ( $\mu\text{g/nmol}$ )	1.3 (0.9 – 2.0)	<b>0.76</b>	<b>&lt; 0.001</b>
U-Long OC/crea ( $\mu\text{g/nmol}$ )	0.02 (0.01 – 0.04)	<b>0.72</b>	<b>&lt; 0.001</b>

Results are shown as median values (interquartile range). Spearman rank correlations (r values) to total skeletal uptake (TSU) of  $^{99m}\text{Tc}$ -MDP are also given.



**Figure 2**  
 The association of total skeletal uptake (TSU) of <sup>99m</sup>Tc-MDP with (A) bone resorption marker, S-TRACP5b,  $r_{(spearman)} = 0.90$ ,  $p < 0.001$  and (B) bone formation marker, S-Total OC,  $r_{(spearman)} = 0.72$ ,  $p < 0.001$ .

**Table 2: Baseline characteristics, BMD, scintigraphy results and bone turnover markers in women with and without a recent fracture.**

	Women with a recent fracture (n = 8)	Women without a recent fracture (n = 14)	p
<b>Anthropometry</b>			
Age (years)	62 (58 – 71)	66 (60 – 73)	0.54
Height (cm)	163 (159 – 168)	162 (157 – 167)	0.68
Weight (kg)	64 (61 – 69)	68 (57 – 84)	0.81
BMI (kg/m <sup>2</sup> )	24.2 (22.6 – 27.5)	26.5 (22.8 – 29.8)	0.41
<b>Bone mass</b>			
Total body BMC (g)	1976 (1929 – 2051)	2127 (1960 – 2247)	0.207
Total body BMD (g/cm <sup>2</sup> )	0.97 (0.94 – 1.04)	1.04 (1.00 – 1.08)	<b>0.041</b>
<b>Scintigraphy</b>			
Total skeletal uptake (%)	28.6 (21.3 – 31.8)	21.6 (17.0 – 24.8)	<b>0.048</b>
<b>Bone formation Markers</b>			
S-Bone ALP (U/L)	27.0 (24.0 – 34.5)	21.0 (16.0 – 25.0)	<b>0.034</b>
S-Total OC (µg/L)	8.2 (5.5 – 13.3)	5.8 (4.4 – 7.3)	<b>0.020</b>
S-OC(1–49) (µg/L)	4.9 (3.0 – 10.0)	2.9 (2.1 – 4.4)	<b>0.031</b>
S-cOC (µg/L)	10.2 (6.6 – 16.5)	6.1 (5.3 – 7.8)	<b>0.017</b>
<b>Bone resorption Markers</b>			
S-TRACP5b (U/L)	3.8 (2.9 – 5.2)	2.8 (2.4 – 3.7)	0.076
S-CTX-I (ng/L)	411 (186 – 639)	203 (173 – 253)	0.066
<b>Urine Osteocalcin</b>			
U-Total OC/crea (µg/nmol)	30.5 (27.0 – 32.1)	25.5 (17.4 – 29.8)	0.13
U-Mid OC/crea (µg/nmol)	1.9 (1.3 – 2.4)	1.1 (0.9 – 1.7)	0.12
U-Long OC/crea (µg/nmol)	0.03 (0.01 – 0.08)	0.02 (0.01 – 0.03)	0.41

Results are shown as median values (inter quartile range). P values for Mann-Whitney U test are also given.

Total OC  $r = 0.72$ , S-Bone ALP  $r = 0.66$ ), but the difference was not statistically significant.

#### **Comparison of women with and without a recent fracture**

We also compared women who had sustained a fracture two years prior to the study ( $n = 8$ ) to the other women ( $n = 14$ ). Women with a recent fracture had lower total body BMD, higher TSU of  $^{99m}\text{Tc}$ -MDP, and higher levels of bone formation markers than women without a recent fracture (Table 2). There were no significant differences in anthropometry, BMC, bone resorption markers or U-OCs, although the levels of resorption markers seemed to be also slightly elevated in the fracture group.

#### **Comparison of women with and without osteoporosis**

There was no statistically significant difference in bone turnover markers or in total skeletal uptake of  $^{99m}\text{Tc}$ -MDP between women with osteoporosis ( $n = 8$ ) and other women ( $n = 14$ ) (data not shown).

#### **Discussion**

We have studied the association between nine bone turnover markers, representing different aspects of bone turnover, and total skeletal metabolism, as assessed by scintigraphic measurement of total skeletal uptake of  $^{99m}\text{Tc}$ -MDP. All bone turnover markers were highly correlated to bone metabolism assessed by total skeletal uptake of  $^{99m}\text{Tc}$ -MDP.

S-TRACP5b and S-CTX-I, the markers of bone resorption, were found to be numerically best correlated with TSU of  $^{99m}\text{Tc}$ -MDP. The correlations for bone formation markers were, however, also highly significant and it was not evident which of the bone turnover markers were associated to total skeletal metabolism the most. Studies with  $^{99m}\text{Tc}$ -MDP suggest that MDP uptake reflects a combination of skeletal blood flow and osteoblastic activity [22,23]. However, markers of bone formation not seemed to be more correlated with such uptake than markers of bone resorption. The lack of difference between formation and resorption markers could be due to the coupling of these two processes. Moreover, studies with radio-labelled bisphosphonates have shown that bisphosphonates localize to regions where new bone is being deposited and newly formed crystals provide a surface area of exposed mineral available to adsorb bisphosphonates, but are also incorporated where osteoclasts are resorbing bone [24].

In addition, the precision and accuracy of the assays for bone turnover markers differ. These differences in assay performance may have influenced the correlations between bone markers and TSU of  $^{99m}\text{Tc}$ -MDP, making the comparison of markers more difficult.

The highest r-value (0.90) was observed for S-TRACP5b. TRACP5b is an enzyme produced by bone-resorbing oste-

oclasts and the activity of TRACP5b in serum reflects the number of active osteoclasts [25,26]. The r-value for S-CTX-I was almost as high (0.80) as for S-TRACP5b. CTX-I results from cathepsin K-mediated degradation of type I collagen by osteoclasts [27]. The number of bone-resorbing osteoclasts (TRACP5b), as well as the amount of degraded type I collagen (CTX-I) should be tightly correlated to the rate of skeletal metabolism. The collection of samples at non-fasting status may, however, have interfered with the correlation for CTX-I, as its levels are known to be influenced by food intake [8].

The r-values for formation markers S-OC and S-bone ALP were slightly lower (0.65 – 0.72). S-OC has a short half-life in circulation [28] and it may be more susceptible to preanalytical variability, such as *in vitro* degradation [29]. Moreover, circulating OC may contain molecules derived from both formation and resorption processes [30]. Bone-specific alkaline phosphatase is an enzyme originating from osteoblasts and needed in osteoid formation and mineralization. Although the methods currently available detect preferentially the bone-specific isoform of the enzyme, they still show a certain degree of cross-reactivity between bone and liver isoforms [31]. The r-values for two of the three urinary OC assays were of similar magnitude (0.72 and 0.76) than for serum OC (0.65, 0.67 and 0.72).

Previous studies on healthy individuals, individuals with endocrine disorders (such as Cushing's syndrome, thyrotoxicosis and primary hyperparathyroidism) or other skeletal diseases (such as heterotrophic pulmonary osteoarthropathy) have shown TSU of  $^{99m}\text{Tc}$ -MDP to be correlated to conventional bone turnover markers such as osteocalcin, urinary deoxypyridinoline [18], total alkaline phosphatase, and urinary hydroxyproline [13,16-18] but data on many currently available, more specific and sensitive bone turnover markers has been lacking.

We did not detect correlation for TSU and age or for TSU and BMD. Previous studies on healthy women, have shown that the TSU of  $^{99m}\text{Tc}$ -MDP is positively correlated with age ( $n = 40, 84$ ) [16,32] and negatively correlated with BMD ( $n = 86$ ) [33]. The absence of such correlation in our study may be due to limited sample size.

When the women who had sustained fractures within two years prior to the study were compared to the others, women with recent fracture had higher level of bone formation markers and higher level of TSU of  $^{99m}\text{Tc}$ -MDP. This is in line with our previous findings that bone formation markers remains elevated up to 1–2 years after fracture [34,35]. Only one out of eight women had visible focal uptake on the scintigram, on the site of prior fracture. Most probably the increase of bone turnover in the fractured individuals is due to the generalized post trauma-

matic skeletal process taking place after fracture [36] as well local increase at the fracture site.

A main strength of this study is that we analyzed several BTMs reflecting different aspects of bone metabolism. In particular, the novel bone turnover markers such as S-TRACP5b and urinary osteocalcins have not been evaluated by using TSU of  $^{99m}\text{Tc}$ -MDP in any of the earlier studies. There are also limitations. Small sample size hindered us to compare which of the BTMs that correlated most with TSU of  $^{99m}\text{Tc}$ -MDP. This should be possible with larger sample sizes, including also samples for relatively high and low levels of formation and resorption, such as children, and patients on anabolic treatments (high bone formation rate), patients with osteolytic bone metastases (high bone resorption rate) or patients on anti-resorptive therapy (low bone formation and resorption rate). Another limitation was with the scanning of scintigraphic procedure used. When we take the whole body image at 3 min, with the speed of 40 cm/min, it took about 3 minutes for the camera to reach the thighs where soft tissue uptake was calculated. It was assumed that 100% of radioisotope is in soft tissue at this early image, but by this time (approximately 6 minutes) some of radioisotope could have already entered the skeleton or filtered by the kidneys. When the study was initiated, information on the effect of feeding on BTMs was not available. Samples were collected without fasting and the non-fasting status may have had minor influence on the results of a few markers, in particular S-CTX-I [8]

## Conclusion

In conclusion, biochemical markers of bone turnover are strongly correlated with the skeletal metabolism as measured by TSU of  $^{99m}\text{Tc}$ -MDP. Although  $^{99m}\text{Tc}$ -MDP uptake is largely driven by osteoblastic activity, there were no significant differences in correlations between skeletal uptake of  $^{99m}\text{Tc}$ -MDP and bone formation markers or bone resorption markers. This could be due to coupling between formation and resorption.

## Abbreviations

$^{99m}\text{Tc}$ -MDP: Technitium 99m labelled methylene diphosphonate; TSU: Total skeletal uptake; BMD: Areal bone mineral density; BMC: Bone mineral content; DXA: Dual energy x-ray absorptiometry; IQR: Inter quartile range; S-Bone ALP: Serum bone specific alkaline phosphatase; S-Total OC: Serum total osteocalcin; S-OC(1-49): Serum intact osteocalcin; S-cOC: Serum carboxylated osteocalcin; S-TRACP5b: Serum tartrate resistant acid phosphatase 5b; S-CTX-I: Serum C-terminal cross-linked telopeptides of type I collagen; U-Total OC/crea: Urinary total osteocalcin to urinary creatinine ratio; U-Mid OC/crea: Urinary mid osteocalcin to urinary creatinine ratio; U-Long OC/crea: Urinary long osteocalcin to urinary creatinine ratio.

## Competing interests

The authors declare that they have no competing interests.

## Authors' contributions

JL was responsible for the progress of the study, performed the statistical analysis, interpreted the data and wrote the manuscript. KN and OT performed the scintigraphy procedure, helped to draft the manuscript and helped commenting on the manuscript. PW was involved in planning of the study and helped to draft the manuscript. KJO designed the study, and helped with interpretation of results, and manuscript writing. KKI analysed the bone turnover markers and was involved in interpretation of results and writing of the manuscript. All authors have read and approved the final manuscript.

## Acknowledgements

This work received financial support from the Swedish Medical Research Council and the Helsingin Sanomain 100-vuotissäätiö Foundation, Finland.

## References

1. Watts NB: **Clinical utility of biochemical markers of bone remodeling.** *Clin Chem* 1999, **45(8 Pt 2)**:1359-1368.
2. Bonnick SL, Shulman L: **Monitoring osteoporosis therapy: bone mineral density, bone turnover markers, or both?** *Am J Med* 2006, **119(4 Suppl 1)**:S25-31.
3. Nenonen A, Cheng S, Ivaska KK, Alatalo SL, Lehtimäki T, Schmidt-Gayk H, Uusi-Rasi K, Heinonen A, Kannus P, Sievanen H, et al.: **Serum TRACP 5b is a useful marker for monitoring alendronate treatment: comparison with other markers of bone turnover.** *J Bone Miner Res* 2005, **20(10)**:1804-1812.
4. Lenora J, Ivaska KK, Obrant KJ, Gerdhem P: **Prediction of bone loss using biochemical markers of bone turnover.** *Osteoporos Int* 2007, **18(9)**:1297-1305.
5. Garner P: **Markers of bone turnover for the prediction of fracture risk.** *Osteoporos Int* 2000, **11(Suppl 6)**:S55-65.
6. Gerdhem P, Ivaska KK, Alatalo SL, Halleen JM, Hellman J, Isaksson A, Pettersson K, Väänänen HK, Åkesson K, Obrant KJ: **Biochemical markers of bone metabolism and prediction of fracture in elderly women.** *J Bone Miner Res* 2004, **19(3)**:386-393.
7. Hannon R, Eastell R: **Preanalytical variability of biochemical markers of bone turnover.** *Osteoporos Int* 2000, **11(Suppl 6)**:S30-44.
8. Clowes JA, Hannon RA, Yap TS, Hoyle NR, Blumsohn A, Eastell R: **Effect of feeding on bone turnover markers and its impact on biological variability of measurements.** *Bone* 2002, **30(6)**:886-890.
9. Papapoulos SE: **Bisphosphonate actions: physical chemistry revisited.** *Bone* 2006, **38(5)**:613-616.
10. Flores LG 2nd, Nagamachi S, Jinnouchi S, Ohnishi T, Futami S, Nakahara H, Tamura S: **Relationship between extraosseous accumulation in bone scintigraphy with  $^{99m}\text{Tc}$ -HMDP and histopathology.** *Nucl Med Commun* 1998, **19(4)**:347-354.
11. Sahin M, Basoglu T, Bernay I, Yapici O, Canbaz F, Yalin T: **Evaluation of metastatic bone disease with pentavalent  $^{99m}\text{Tc}$ (m)-dimer-captosuccinic acid: a comparison with whole-body scanning and 4/24 hour quantitation of vertebral lesions.** *Nucl Med Commun* 2000, **21(3)**:251-258.
12. Fogelman I, Bessent RG, Turner JG, Citrin DL, Boyle IT, Greig WR: **The use of whole-body retention of  $\text{Tc-}^{99m}$  diphosphonate in the diagnosis of metabolic bone disease.** *J Nucl Med* 1978, **19(3)**:270-275.
13. Thomsen K, Johansen J, Nilas L, Christiansen C: **Whole body retention of  $^{99m}\text{Tc}$ -diphosphonate. Relation to biochemical indices of bone turnover and to total body calcium.** *Eur J Nucl Med* 1987, **13(1)**:32-35.
14. D'Addabbo A, Rubini G, Mele M, Lauriero F: **A new method for assessing  $^{99m}\text{Tc}$ -MDP bone uptake from a bone scan image:**



- quantitative measurement of radioactivity in global skeletal regions of interest. *Nucl Med Commun* 1992, **13**(1):55-60.
15. Brenner W, Bohuslavizki KH, Sieweke N, Tinnemeyer S, Clausen M, Henze E: **Quantification of diphosphonate uptake based on conventional bone scanning.** *Eur J Nucl Med* 1997, **24**(10):1284-1290.
  16. Carnevale V, Frusciante V, Scillitani A, Modoni S, Pileri M, Chiodini I, Dicembrino F, Romagnoli E, Minisola S: **Age-related changes in the global skeletal uptake of technetium-99m methylene diphosphonate in healthy women.** *Eur J Nucl Med* 1996, **23**(11):1473-1477.
  17. Minisola S, Pacitti MT, Romagnoli E, Rosso R, Carnevale V, Caravella P, Scillitani A, Dicembrino F: **Clinical validation of a new immunoradiometric assay for intact human osteocalcin.** *Calcif Tissue Int* 1999, **64**(5):365-369.
  18. Scillitani A, Dicembrino F, Chiodini I, Minisola S, Fusilli S, Di Giorgio A, Garrubba M, D'Aloiso L, Frusciante V, Torlontano M, et al.: **Global skeletal uptake of 99mTc-methylene diphosphonate (GSU) in patients affected by endocrine diseases: comparison with biochemical markers of bone turnover.** *Osteoporos Int* 2002, **13**(10):829-834.
  19. Käkönen SM, Hellman J, Karp M, Laaksonen P, Obrant KJ, Väänänen HK, Lövgren T, Pettersson K: **Development and evaluation of three immunofluorometric assays that measure different forms of osteocalcin in serum.** *Clin Chem* 2000, **46**(3):332-337.
  20. Halleen JM, Alatalo SL, Suominen H, Cheng S, Janckila AJ, Väänänen HK: **Tartrate-resistant acid phosphatase 5b: a novel serum marker of bone resorption.** *J Bone Miner Res* 2000, **15**(7):1337-1345.
  21. Ivaska KK, Käkönen SM, Gerdhem P, Obrant KJ, Pettersson K, Väänänen HK: **Urinary osteocalcin as a marker of bone metabolism.** *Clin Chem* 2005, **51**(3):618-628.
  22. Moore AE, Blake GM, Fogelman I: **Quantitative measurements of bone remodeling using 99mTc-methylene diphosphonate bone scans and blood sampling.** *J Nucl Med* 2008, **49**(3):375-382.
  23. Blake GM, Park-Holohan SJ, Cook GJ, Fogelman I: **Quantitative studies of bone with the use of 18F-fluoride and 99mTc-methylene diphosphonate.** *Semin Nucl Med* 2001, **31**(1):28-49.
  24. Masarachia P, Weinreb M, Balena R, Rodan GA: **Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones.** *Bone* 1996, **19**(3):281-290.
  25. Alatalo SL, Halleen JM, Hentunen TA, Monkkonen J, Väänänen HK: **Rapid screening method for osteoclast differentiation in vitro that measures tartrate-resistant acid phosphatase 5b activity secreted into the culture medium.** *Clin Chem* 2000, **46**(11):1751-1754.
  26. Alatalo SL, Ivaska KK, Waguespack SG, Econs MJ, Väänänen HK, Halleen JM: **Osteoclast-derived serum tartrate-resistant acid phosphatase 5b in Albers-Schonberg disease (type II autosomal dominant osteopetrosis).** *Clin Chem* 2004, **50**(5):883-890.
  27. Garnero P, Ferreras M, Karsdal MA, Nicamhloibh R, Risteli J, Borel O, Qvist P, Delmas PD, Foged NT, Delaisse JM: **The type I collagen fragments ICTP and CTX reveal distinct enzymatic pathways of bone collagen degradation.** *J Bone Miner Res* 2003, **18**(5):859-867.
  28. Price PA, Williamson MK, Lothringer JW: **Origin of the vitamin K-dependent bone protein found in plasma and its clearance by kidney and bone.** *J Biol Chem* 1981, **256**(24):12760-12766.
  29. Garnero P, Grimaux M, Seguin P, Delmas PD: **Characterization of immunoreactive forms of human osteocalcin generated in vivo and in vitro.** *J Bone Miner Res* 1994, **9**(2):255-264.
  30. Ivaska KK, Hentunen TA, Vääräniemi J, Ylipahkala H, Pettersson K, Väänänen HK: **Release of intact and fragmented osteocalcin molecules from bone matrix during bone resorption in vitro.** *J Biol Chem* 2004, **279**(18):18361-18369.
  31. Seibel MJ: **Molecular markers of bone turnover: biochemical, technical and analytical aspects.** *Osteoporos Int* 2000, **11**(Suppl 6):S18-29.
  32. Carnevale V, Dicembrino F, Frusciante V, Chiodini I, Minisola S, Scillitani A: **Different patterns of global and regional skeletal uptake of 99mTc-methylene diphosphonate with age: relevance to the pathogenesis of bone loss.** *J Nucl Med* 2000, **41**(9):1478-1483.
  33. Kigami Y, Yamamoto I, Ohnishi H, Takada M, Matsushita R, Hamanaka Y, Ota T, Morita R: **Relationship between skeletal uptake of 99mTc-HMDP and bone mineral density in elderly women.** *Ann Nucl Med* 1998, **12**(1):15-20.
  34. Obrant KJ, Ivaska KK, Gerdhem P, Alatalo SL, Pettersson K, Väänänen HK: **Biochemical markers of bone turnover are influenced by recently sustained fracture.** *Bone* 2005, **36**(5):786-792.
  35. Ivaska KK, Gerdhem P, Åkesson K, Garnero P, Obrant KJ: **Effect of fracture on bone turnover markers: a longitudinal study comparing marker levels before and after injury in 113 elderly women.** *J Bone Miner Res* 2007, **22**(8):1155-1164.
  36. Obrant KJ, Nilsson BE: **Histomorphologic changes in the tibial epiphysis after diaphyseal fracture.** *Clin Orthop Relat Res* 1984:270-275.

### Pre-publication history

The pre-publication history for this paper can be accessed here:

<http://www.biomedcentral.com/1756-6649/9/3/prepub>

Publish with **BioMed Central** and every scientist can read your work free of charge

"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

